http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Varian and Google Cloud Collaborate to Aid in the Fight Against Cancer
-
Varian Medical Systems Invests in Bend It Technologies, Ltd., a Company Developing Novel Steerable Microcatheters
-
Varian Announces CEO Succession Plan
-
CTSI Oncology Solutions, a Varian Company, to Provide Technology-Enabled Services for Radiation Oncology at CHRISTUS Health
-
Varian Becomes First Medical Technology Company Joining the Cancer Drug Development Forum
-
Varian Installs World's First ProBeam® 360° Proton Therapy System at Penn Medicine Lancaster General Health
-
Varian Reports Results for First Quarter of Fiscal Year 2021
-
Varian Ranked Highest in Survey of US Radiation Oncology Professionals
-
Varian Announces First Quarter Fiscal Year 2021 Earnings Release Date
-
Varian and the Cincinnati Children's/UC Health Proton Therapy Center Announce Initial Patient Treated in the FAST-01 First Human Clinical Trial of FLASH Therapy for Cancer
-
Varian Medical Systems (VAR) announces new $10M investment and collaboration agreement with COTA
-
Varian Medical Systems Invests in COTA, Inc. to Help Drive Faster, More Accurate Data-Driven Cancer Care
-
Varian Reports Results for Fourth Quarter of Fiscal Year 2020
-
Varian Congratulates Historic Trade Package Agreement with Brazil
-
Varian Announces Presence at American Society for Radiation Oncology (ASTRO) Annual Meeting Highlighting Advancements in Intelligent Cancer Care™
-
Varian Announces Fourth Quarter Fiscal Year 2020 Earnings Release Date
-
Varian (VAR) Stockholders Approve Combination with Siemens Healthineers
-
Varian Stockholders Approve Combination with Siemens Healthineers
-
Varian Medical Systems (VAR) Receives Investigational Device Exemption and Prepares for First Ever Clinical Trial of FLASH Therapy
-
Varian Receives Investigational Device Exemption (IDE) and Prepares for First Ever Clinical Trial of FLASH Therapy
-
Varian Medical Systems (VAR) Expects to Benefit from the Extension of Medical Linear Accelerators Tariff Exclusion in China
-
Varian Expects to Benefit from the Extension of Medical Linear Accelerators Tariff Exclusion in China
-
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
-
Varian Medical Systems (VAR) Announces Chris Toth as President and CEO
-
Varian Announces Appointment of Chris Toth as President and Chief Operating Officer
-
Varian Announces Goshen Center for Cancer Care Treats First Patient with Ethos® Therapy, Expanding Access to Personalized Cancer Care
-
Germany's first Ethos Therapy Ordered by the German Cancer Research Center
-
Varian (VAR) Agrees to Be Acquired by Siemens Healthineers for $177.50/Share, or $16.4B
-
Varian Reports Results for Third Quarter of Fiscal Year 2020
-
Varian to Combine with Siemens Healthineers in $16.4 Billion All-Cash Transaction
-
Varian Announces Third Quarter Fiscal Year 2020 Earnings Release Date
-
Varian Wins "Best After-Sales Service Award for Radiotherapy Products" in China For Third Year In A Row
-
Long-Term Results from SABR-COMET Further Demonstrate Effectiveness of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Metastatic Cancers
-
Varian Appoints Michael Hutchinson to Senior Vice President, Chief Legal Officer, and Francis R. Facchini, M.D., FSIR to President, Interventional Solutions Business
-
Varian to Participate in Goldman Sachs Global Virtual Healthcare Conference
-
Varian to Participate in Jefferies Virtual Healthcare Conference
-
Varian Launches New Noona® Capabilities to Meet Growing Demand for Remote Cancer Patient Monitoring in Response to COVID-19's Impact on Healthcare
-
Varian Announces New Addition to FlashForward Consortium
-
Varian to Participate in UBS Virtual Global Healthcare Conference
-
Center in Singapore Expanding Access to Radiation Therapy Technology in the Fight Against Cancer
-
Varian Reports Results for Second Quarter of Fiscal Year 2020; Withdraws 2020 Guidance
-
Varian Announces Second Quarter Fiscal Year 2020 Earnings Release Date
-
Varian Brings Machine Learning to Proton Treatment Planning with Eclipse v16
-
Alabama's Only Proton Therapy Center Treats First Patient with Varian ProBeam
-
Varian to Equip New Ethos Personalized Adaptive Therapy Center in Phoenix
-
Varian (VAR) Halcyon 2.0 Treatment System Receives China NMPA Approval
-
Varian Halcyon 2.0 Treatment System Receives China NMPA Approval
-
Quebec Selects Varian to Increase Access to Advanced Cancer Care
-
Ethos Therapy Continues Global Expansion
-
Varian (VAR) says COVID-19 outbreak will negatively impact operating results

